Literature DB >> 20876743

Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits.

Lioubov I Brueggemann1, Alexander R Mackie, Jody L Martin, Leanne L Cribbs, Kenneth L Byron.   

Abstract

KCNQ4 and KCNQ5 potassium channel subunits are expressed in vascular smooth muscle cells, although it remains uncertain how these subunits assemble to form functional channels. Using patch-clamp techniques, we compared the electrophysiological characteristics and effects of diclofenac, a known KCNQ channel activator, on human KCNQ4 and KCNQ5 channels expressed individually or together in A7r5 rat aortic smooth muscle cells. The conductance curves of the overexpressed channels were fitted by a single Boltzmann function in each case (V(0.5) values: -31, -44, and -38 mV for KCNQ4, KCNQ5, and KCNQ4/5, respectively). Diclofenac (100 μM) inhibited KCNQ5 channels, reducing maximum conductance by 53%, but increased maximum conductance of KCNQ4 channels by 38%. The opposite effects of diclofenac on KCNQ4 and KCNQ5 could not be attributed to the presence of a basic residue (lysine) in the voltage-sensing domain of KCNQ5, because mutation of this residue to neutral glycine (the residue present in KCNQ4) resulted in a more effective block of the channel. Differences in deactivation rates and distinct voltage-dependent effects of diclofenac on channel activation and deactivation observed with each of the subunit combinations (KCNQ4, KCNQ5, and KCNQ4/5) were used as diagnostic tools to evaluate native KCNQ currents in vascular smooth muscle cells. A7r5 cells express only KCNQ5 channels endogenously, and their responses to diclofenac closely resembled those of the overexpressed KCNQ5 currents. In contrast, mesenteric artery myocytes, which express both KCNQ4 and KCNQ5 channels, displayed whole-cell KCNQ currents with properties and diclofenac responses characteristic of overexpressed heteromeric KCNQ4/5 channels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876743      PMCID: PMC3014280          DOI: 10.1124/mol.110.067496

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

1.  Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways.

Authors:  Kyle K Henderson; Kenneth L Byron
Journal:  J Appl Physiol (1985)       Date:  2007-01-04

2.  The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.

Authors:  Karen Padilla; Alan D Wickenden; Aaron C Gerlach; Ken McCormack
Journal:  Neurosci Lett       Date:  2009-09-03       Impact factor: 3.046

3.  Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells.

Authors:  Lioubov I Brueggemann; Christopher J Moran; John A Barakat; Jay Z Yeh; Leanne L Cribbs; Kenneth L Byron
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-10-27       Impact factor: 4.733

4.  Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Bharath K Mani; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2009-07-15       Impact factor: 4.436

5.  Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity.

Authors:  S Y M Yeung; V Pucovský; J D Moffatt; L Saldanha; M Schwake; S Ohya; I A Greenwood
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

6.  KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle.

Authors:  Shreena Joshi; Vojtech Sedivy; Daniel Hodyc; Jan Herget; Alison M Gurney
Journal:  J Pharmacol Exp Ther       Date:  2009-01-16       Impact factor: 4.030

7.  Opposite regulation of KCNQ5 and TRPC6 channels contributes to vasopressin-stimulated calcium spiking responses in A7r5 vascular smooth muscle cells.

Authors:  Bharath K Mani; Lioubov I Brueggemann; Leanne L Cribbs; Kenneth L Byron
Journal:  Cell Calcium       Date:  2009-02-25       Impact factor: 6.817

8.  N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.

Authors:  A D Wickenden; J L Krajewski; B London; P K Wagoner; W A Wilson; S Clark; R Roeloffs; G McNaughton-Smith; G C Rigdon
Journal:  Mol Pharmacol       Date:  2007-12-18       Impact factor: 4.436

9.  Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.

Authors:  Anne Schenzer; Thomas Friedrich; Michael Pusch; Paul Saftig; Thomas J Jentsch; Joachim Grötzinger; Michael Schwake
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

10.  A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives.

Authors:  Asher Peretz; Nurit Degani-Katzav; Maya Talmon; Eyal Danieli; Anna Gopin; Eti Malka; Rachel Nachman; Amiram Raz; Doron Shabat; Bernard Attali
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

View more
  28 in total

1.  Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy.

Authors:  Lioubov I Brueggemann; Priyanka P Kakad; Robert B Love; Julian Solway; Maria L Dowell; Leanne L Cribbs; Kenneth L Byron
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-30       Impact factor: 5.464

2.  Zonal variations in K+ currents in vestibular crista calyx terminals.

Authors:  Frances L Meredith; Katherine J Rennie
Journal:  J Neurophysiol       Date:  2014-10-15       Impact factor: 2.714

3.  Thalamic Kv 7 channels: pharmacological properties and activity control during noxious signal processing.

Authors:  Manuela Cerina; Hanna J Szkudlarek; Philippe Coulon; Patrick Meuth; Tatyana Kanyshkova; Xuan Vinh Nguyen; Kerstin Göbel; Thomas Seidenbecher; Sven G Meuth; Hans-Christian Pape; Thomas Budde
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

4.  Effects of KCNQ channel modulators on the M-type potassium current in primate retinal pigment epithelium.

Authors:  Bikash R Pattnaik; Bret A Hughes
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-30       Impact factor: 4.249

5.  Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58.

Authors:  F Zhang; Y Mi; J L Qi; J W Li; M Si; B C Guan; X N Du; H L An; H L Zhang
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Differential protein kinase C-dependent modulation of Kv7.4 and Kv7.5 subunits of vascular Kv7 channels.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Leanne L Cribbs; Jessica Freda; Abhishek Tripathi; Matthias Majetschak; Kenneth L Byron
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

Review 7.  One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.

Authors:  T A Jepps; S P Olesen; I A Greenwood
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

8.  Selective activation of vascular Kv 7.4/Kv 7.5 K+ channels by fasudil contributes to its vasorelaxant effect.

Authors:  Xuan Zhang; Hailong An; Junwei Li; Yuanyuan Zhang; Yang Liu; Zhanfeng Jia; Wei Zhang; Li Chu; Hailin Zhang
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

9.  Kv7.5 Potassium Channel Subunits Are the Primary Targets for PKA-Dependent Enhancement of Vascular Smooth Muscle Kv7 Currents.

Authors:  Bharath K Mani; Christina Robakowski; Lyubov I Brueggemann; Leanne L Cribbs; Abhishek Tripathi; Matthias Majetschak; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2015-12-23       Impact factor: 4.436

10.  Differential activation of vascular smooth muscle Kv7.4, Kv7.5, and Kv7.4/7.5 channels by ML213 and ICA-069673.

Authors:  Lyubov I Brueggemann; Jennifer M Haick; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2014-06-18       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.